Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo
viaeconomictimes.indiatimes.com21 Sept
Biocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, for HER2-positive breast cancer. The Euro
Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.
Read the full story on economictimes.indiatimes.com ↗